Abstract
BackgroundPatients diagnosed as diffuse large B cell lymphoma (DLBCL) with CD5 positive normally have a worse outcome and poorly respond to the regulatory treatment strategy.ResultsWe recently reported differently expressed tRFs and their potential target-genes of tRFs in patients with CD5+ R/R DLBCL. Differently expressed tRFs were detected by Illumina NextSeq instrument and the results were verified by quantitative real-time reverse transcription-PCR. tRF2Cancer database was searched to compared with the results. Further research was performed through bio-informatic analysis including gene ontology (GO) and pathway enrichment analyses, etc. A total of 308 tRFs were identified. Two sequences (AS-tDR-008946, AS-tDR-013492) were chosen for further investigated.ConclusionsThe results of Bioinformatics analysis revealed that the target genes including NEDD4L and UBA52 and several associated pathways including PI3K/AKT and MAPK/ERK might be involved in the development of CD5+ R/R DLBCL. Our preliminary study on the associated tRFs might provide a valuable measure to explore the pathogenesis and progression of CD5+ R/R DLBCL.ReviewersThis article was reviewed by Zhen Qing Ye, Nagarajan Raju and Jin Zhuang Dou.
Highlights
Patients diagnosed as diffuse large B cell lymphoma (DLBCL) with CD5 positive normally have a worse outcome and poorly respond to the regulatory treatment strategy
We aimed to investigate the profiles of differently expressed tRFs between CD5+ R/R DLBCL and healthy individuals
Overview of the tRFs & tiRNAs profiling To determine the differently expressed tRFs & tiRNAs profiles in CD5+ R/R DLBCL, we recruited three cases and three healthy controls. Their blood RNAs were sequenced with RNA-sequencing technology. (GSE140225 ) after quality control filtering of the raw sequencing reads, 12,106,086, 11,250,357 and 11,481,802 clean reads were generated for three CD5+ R/R DLBCL patients, and 7,815,334, 9,634,464 and 9,365,532 clean reads were generated for three healthy controls
Summary
Patients diagnosed as diffuse large B cell lymphoma (DLBCL) with CD5 positive normally have a worse outcome and poorly respond to the regulatory treatment strategy. The tRFs, which derived from tRNA cleavage in a specific manner, are groups of abundant non-coding RNAs only less than miRNAs and were proved can play roles. It has been reported that tRFs participate in many biological processes including cell proliferation, viral reverse transcriptase activation, gene expression, RNA procession regulation, DNA damage response modulation, and tumor suppression [10]. The former study had proved that a tRF sequence is down-regulated in B cell lymphoma and can modulate proliferation and the DNA damage response [11]. The most significantly expressed tRFs and their potential target genes will be discussed by bio-informatic analysis in our study
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
